Home > Search Results: keywords:"Neuromyelitis optica"
Search:
Search Tips :: Advanced Search
Search collections:
Sort by: Display results: Output format:
National Repository of Grey Literature 2 records found  Search took 0.00 seconds. 
MRI mapping of brain iron deposition in patients with neurological diseases with a focus on multiple sclerosis and neuromyelitis optica
 Pudlač, Adam ; Burgetová, Andrea (advisor) ; Lisý, Jiří (referee) ; Ryška, Pavel (referee)
Background: Neuromyelitis optica (NMO) and multiple sclerosis (MS) often manifest similar symptoms. However, the distinction between the two diseases is particularly important for different therapies. The aim of this study is to determine whether these diseases can be distinguished based on cerebral iron deposits in the deep grey matter and whether there is a correlation between iron deposits, local deep grey matter atrophy and clinical severity of the disease. Methods: 40 patients with relapsing-remitting MS (RRMS), 20 patients with NMO and 20 healthy subjects were examined at the MRI department of the 1st Faculty of Medicine of Charles University in Prague from December 2013 to March 2015. All patients with RRMS fulfilled the revised McDonald criteria, the diagnosis of NMO was based on Wingerchuk criteria. All 20 patients with NMO had positive AQP4-IgG. Quantitative susceptibility mapping (QSM) and volumometry of individual deep gray matter structures were performed. All patients with NMO and MS underwent simultaneous examination by a specialist in demyelinating diseases. Neurological disability was assessed by the Kurtzke Disability Status Scale (EDSS). Results: Patients with NMO have higher magnetic susceptibility values in the substantia nigra compared to healthy controls. Patients with RRMS...
Detailed record
Lymphocyte subpopulations, cytokine production and stem cells transplantation in multiple sclerosis patients
 Krasulová, Eva ; Kubala Havrdová, Eva (advisor) ; Ehler, Edvard (referee) ; Syková, Eva (referee)
Multiple sclerosis (MS) represents a demyelinating disease of the central nervous system with known autoimmune etiology. Currently new diagnostic criteria are used allowing us to diagnose MS early after first relapse of clinical symptoms. Several drugs are available to reduce disease activity and postpone later MS stages with irreversible disability. Prognosis of an individual patient and accurate treatment is however defined only imperfectly based on our clinical experience and brain magnetic resonance imaging. Specific prognostic markers are missing. Aims: 1. To identify suitable prognostic immunological marker from peripheral blood of MS patients in different disease stages and under different treatment regimens; 2. To describe group of MS patients treated with autologous stem cells transplantation (ASCT) or allogeneic stem cells transplantation (alloSCT) with respect to efficacy, adverse events and accurate patient selection. Patients and methods: In the first part of the study we involved 33 patients with clinically isolated syndrome, 17 MS patients treated with natalizumab and 14 patients with aggressive MS treated with ASCT. Disability measured by Expanded Disability Status Scale (EDSS) as well as relapse rate were evaluated before treatment (baseline) and after 3, 6, 12 and 24 months after...
Detailed record

Interested in being notified about new results for this query?
Subscribe to the RSS feed.
Digital Repository :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.2
Maintained by admin.invenio@techlib.cz
This site is also available in the following languages:
Česky  English